ImageneBio, Inc.

InmageneBiotechnologyChina

73% match

Inmagene Biopharmaceuticals is a clinical-stage biotechnology company headquartered in San Diego, California. The firm is dedicated to the research, development, and advancement of novel therapeutic medicines. It operates within the life sciences sector, focusing on clinical development and corporate mergers.

Jade Biosciences, Inc.JBIO · BiotechnologyWaltham, United States

71% matchPublic

Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.

Attovia Therapeutics, Inc.ATTO · BiotechSan Carlos, United States

71% matchPublic

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

IMAGINAB, INC.BiotechnologyUnited States

70% matchPrivate

ImaginAb, Inc. is a global biotechnology company headquartered in California, with operations in Los Angeles and San Diego. It focuses on developing next-generation imaging and radiopharmaceutical products for cancer immunology.

IMAGINE PHARMA LLCBiotechnologyUnited States

70% matchPrivate

Imagine Pharma LLC is a biotechnology company that develops novel polypeptide-based platforms focused on oral delivery for biologic drugs, therapeutics for various disease states, and regenerative medicine. The company aims to create first-in-class treatments for conditions such as diabetes and wound healing, alongside offering oral peptide dietary supplements and functional ingredients for consumers.

Q32 Bio Inc. is a clinical-stage biotechnology company, headquartered in Waltham, Massachusetts, focused on creating innovative biologic treatments. Operating within the United States, its primary objective is to re-establish a healthy immune balance in individuals suffering from autoimmune and inflammatory conditions stemming from pathological immune dysfunction. The company's primary therapeutic candidate, ADX-097, is a humanized monoclonal antibody fusion protein engineered to restore proper complement regulation. This compound has successfully concluded its Phase I clinical trial and is being advanced for the treatment of severe renal and other complement-mediated diseases that present significant unmet medical needs. These include specific conditions like lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. Furthermore, Q32 Bio is progressing Bempikibart (ADX-914), a fully human monoclonal antibody that functions as an interleukin-7 receptor alpha antagonist. By disrupting the signaling pathways mediated by interleukin-7 and thymic stromal lymphopoietin, Bempikibart aims to normalize adaptive immune function. This promising candidate is currently undergoing Phase II clinical trials for the management of atopic dermatitis and alopecia areata. The company, established in 2017, was previously known as AdMIRx Inc. and rebranded to Q32 Bio Inc. in April 2020.